NRG-103 injection for recurrent glioblastoma patients
Part of Cancer clinical trials.
This trial tests an injection called NRG-103 given directly into the cavity where a recurrent brain tumor was removed. It is for people with glioblastoma that has come back and who have already had standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a confirmed diagnosis of recurrent glioblastoma (a type of brain tumor).
- The recurrent tumor must have been surgically removed, and a small reservoir (Ommaya) must have been placed in the cavity.
- You should be in good overall health, able to care for yourself (Karnofsky score 70 or higher), and have stable or decreasing steroid use.
- Your blood counts, liver, kidney, and heart function must be within safe limits.
- You cannot have other serious conditions like active hepatitis, severe heart disease, or a history of certain other cancers or immune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called NRG-103 for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard treatments. The goal is to see if it's safe and if it might help shrink the tumor.
This trial is testing a new drug (JL15003) given directly into the brain tumor using a small device called an Ommaya reservoir. It is for people whose glioblastoma has come back despite standard treatments. You will need to have had a polio vaccine booster before starting.
This trial tests a new injection called VRT106 for people whose glioblastoma (a brain tumor) has come back or is growing. It uses a virus that may help the immune system attack the tumor. This study is for those who have not had a similar virus or gene therapy before.
This trial tests a new drug called CM93 that targets a specific change (EGFR) in recurrent glioblastoma, a type of brain cancer. The goal is to see if it can slow or stop tumor growth and to find the best dose.
This trial tests a new drug called ACT001 for people with recurrent glioblastoma (a type of brain cancer) whose tumors have a specific marker (STAT3-high). The drug targets that marker to try to stop the tumor from growing.
This study tests an experimental treatment given after the standard first treatment (chemotherapy and radiation) for newly diagnosed glioblastoma, a type of brain cancer. It aims to see if this extra treatment helps keep the cancer from coming back.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.